Evidence map›Paper›PMID 39711733›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Androgen receptor drives polyamine synthesis creating a vulnerability for prostate cancer.

Rajendra Kumar, Sheila Jonnatan, David E Sanin, Varsha Vakkala, Anoushka Kadam, Shivani Kumar, Susan L Dalrymple, Liang Zhao, Jackson Foley, Cassandra E Holbert and 15 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Rajendra Kumar
Sheila Jonnatan
David E Sanin
Varsha Vakkala
Anoushka Kadam
Shivani Kumar
Susan L Dalrymple
Liang Zhao
Jackson Foley
Cassandra E Holbert
Ashley Nwafor
Srushti Kittane
Elizabeth Penner
Petya Apostolova
Samuel Warner
Chi V Dang
Eneda Toska
Elizabeth A Thompson
John T Isaacs
Angelo M De Marzo
Erika L Pearce
Tracy Murray Stewart
Robert A Casero
Samuel R Denmeade
Laura A Sena

Funding

TRAINING IN AREAS FUNDAMENTAL TO CANCER RESEARCHT32CA009110 · NCI · JOHNS HOPKINS UNIVERSITY · PI MATUNIS, MICHAEL J., WEERARATNA, ASHANI T · 1985 to 2025
$13.1M
Synthetic lethal metabolic drug combinations for castration-resistant prostate cancerK08CA273167 · NCI · JOHNS HOPKINS UNIVERSITY · PI Laura A. Sena · 2023 to 2026
$877k
NCI NIH HHS K08 CA273167NCI NIH HHS T32 CA009110
6 · The paper itself

Abstract

Supraphysiological androgen (SPA) treatment can paradoxically restrict growth of castration-resistant prostate cancer with high androgen receptor (AR) activity, which is the basis for use of Bipolar Androgen Therapy (BAT) for patients with this disease. While androgens are widely appreciated to enhance anabolic metabolism, how SPA-mediated metabolic changes alter prostate cancer progression and therapy response is unknown. Here, we report that SPA markedly increased intracellular and secreted polyamines in prostate cancer models. This occurred through AR binding at enhancer sites upstream of the

Identifiers

PMID39711733
PMCPMC11661327

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.